Welcome to our dedicated page for ISLE news (Ticker: ISLE), a resource for investors and traders seeking the latest updates and insights on ISLE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ISLE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ISLE's position in the market.
Isleworth Healthcare Acquisition Corp. (Nasdaq: ISLE) has canceled its special shareholder meeting scheduled for August 26, 2022, and will redeem all outstanding public shares effective August 29, 2022. This decision comes as the company failed to complete an initial business combination by the September 1, 2022 deadline. Shareholders will receive approximately $10.01 per share upon redemption. Following the redemption, the company's public shares will be deemed cancelled, and the company plans to delist from Nasdaq and liquidate its assets in compliance with Delaware law.
Isleworth Healthcare Acquisition Corporation (Nasdaq: ISLE) has announced the termination of its merger agreement with Cytovia Holdings, Inc. effective immediately. The decision includes mutual releases and covenants not to sue, indicating a formal end to discussions that began in April 2022. The details of the termination are documented in a Current Report on Form 8-K filed today. Isleworth specializes in mergers and acquisitions within the life sciences sector, leveraging extensive industry expertise.
Cytovia Therapeutics presented findings at the European Hematology Association's annual congress on June 10, 2022, supporting the development of CYT-338, a new NK cell engager for treating relapsed/refractory multiple myeloma. The data indicated that CYT-338 shows three times better binding to CD38-expressing cells than daratumumab, with effective in vitro and in vivo results demonstrating tumor growth inhibition and improved survival rates. The company is moving forward with its therapeutic development, potentially enhancing its market position in cancer therapies.
Cytovia Therapeutics will present at the Annual EHA 2022 Hybrid Congress from June 9-12, 2022 in Vienna, Austria. The poster will feature their novel CD38 NKP46 FLEX-NK engager, CYT-338, which targets multiple myeloma cells. Initial findings indicate CYT-338 has significantly improved binding and cytolytic activity compared to daratumumab. This presentation underscores Cytovia's commitment to advancing innovative cell therapies in oncology. Furthermore, it comes amid Cytovia's planned merger with Isleworth Healthcare Acquisition Corp. (ISLE), expected to finalize in H2 2022.
Cytovia Therapeutics announced its participation at the AACR Special Conference on Advances in Liver Cancer, held from May 5-8, 2022, in Boston, Massachusetts. The company will present its poster titled "Preclinical activity of glypican-3 (GPC3) and NKp46 directed FLEX-NK™ engager antibody (CYT-303) in combination with iPSC derived natural killer cells" on May 6. The poster's findings highlight CYT-303's potent anti-tumor activity against hepatocellular carcinoma (HCC), supporting further clinical development. Isleworth Healthcare Acquisition Corp. (NASDAQ: ISLE) is involved in a business combination with Cytovia Holdings, Inc.
Isleworth Healthcare Acquisition Corp. (NASDAQ: ISLE) received a notice from Nasdaq on May 28, 2021, indicating non-compliance with Listing Rule 5250(c)(1) due to a delay in filing its Quarterly Report on Form 10-Q for Q1 2021. This delay stems from a reevaluation of warrant accounting following an SEC statement on SPACs issued on April 12, 2021. The Company has 60 days to submit a compliance plan, potentially extending the deadline for filing until November 22, 2021. The notice currently does not impact the trading of ISLE's securities.
FAQ
What is the market cap of ISLE (ISLE)?
